Ma Tiancheng, Sun Yu, Jiang Chang, Xiong Weilin, Yan Tingxu, Wu Bo, Jia Ying
School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Wenhua Road 103, Shenyang 110016, China.
Research Institute of Medicine and Pharmacy, Qiqihar Medical University, Bukui North Street 333, Qiqihar 161006, China.
Evid Based Complement Alternat Med. 2021 Jun 30;2021:7127129. doi: 10.1155/2021/7127129. eCollection 2021.
The purpose of our research is to systematically explore the multiple mechanisms of Flowers (HF) on depressive disorder (DD).
The components of HF were searched from the literature. The targets of components were obtained from PharmMapper. After that, Cytoscape software was used to build a component-target network. The targets of DD were collected from DisGeNET, PharmGKB, TTD, and OMIM. Protein-protein interactions (PPIs) among the DD targets were executed to screen the key targets. Afterward, the GO and KEGG pathway enrichment analysis were performed by the KOBAS database. A compound-target-KEGG pathway network was built to analyze the key compounds and targets. Finally, the potential active substances and targets were validated by molecular docking.
A total of 55 active compounds in HF, 646 compound-related targets, and 527 DD-related targets were identified from public databases. After treated with PPI, 219 key targets of DD were acquired. The gene enrichment analysis suggested that HF probably benefits DD patients by modulating pathways related to the nervous system, endocrine system, amino acid metabolism, and signal transduction. The network analysis showed the critical components and targets of HF on DD. Results of molecular docking increased the reliability of this study.
It predicted and verified the pharmacological and molecular mechanism of HF against DD from a holistic perspective, which will also lay a foundation for further experimental research and rational clinical application of DD.
本研究旨在系统探讨花(HF)治疗抑郁症(DD)的多种机制。
从文献中检索HF的成分。从PharmMapper获取成分的靶点。之后,使用Cytoscape软件构建成分-靶点网络。从DisGeNET、PharmGKB、TTD和OMIM收集DD的靶点。对DD靶点之间的蛋白质-蛋白质相互作用(PPI)进行分析以筛选关键靶点。随后,通过KOBAS数据库进行基因本体论(GO)和京都基因与基因组百科全书(KEGG)通路富集分析。构建化合物-靶点-KEGG通路网络以分析关键化合物和靶点。最后,通过分子对接验证潜在的活性物质和靶点。
从公共数据库中鉴定出HF中的55种活性化合物、646个化合物相关靶点和527个DD相关靶点。经PPI处理后,获得了219个DD的关键靶点。基因富集分析表明,HF可能通过调节与神经系统、内分泌系统、氨基酸代谢和信号转导相关的通路使DD患者受益。网络分析显示了HF对DD的关键成分和靶点。分子对接结果提高了本研究的可靠性。
从整体角度预测并验证了HF抗DD的药理和分子机制,这也将为DD的进一步实验研究和合理临床应用奠定基础。